Merck KGaA is bringing cladribine--the multiple sclerosis pill scuttled by regulatory rejections on both sides of the Atlantic four years ago--back from the dead.
Scientists in Scotland have been grabbing headlines with news that their preclinical research into an experimental single-dose antimalaria compound has shown real promise, spurring Merck KGaA to pick up the development and commercialization rights.
Merck KGaA, long plagued by clinical setbacks, is pushing into Phase III with a Pfizer-partnered cancer treatment, believing it can eventually catch up with rivals already on the market.
Four months after Pfizer stepped up with a $2.85 billion promise to partner with Merck KGaA on a preclinical PD-L1 oncology effort, the German pharma company has turned around to partner with Intrexon on an upstart CAR-T cancer drug development project.
After gaining an option on Opexa's experimental drug for secondary progressive multiple sclerosis for only $5 million, Merck KGaA's Serono division has come up with an extra $3 million to support the biotech's ongoing Phase IIb study.
Anyone looking for some perspective on Merck KGaA's recent R&D cutbacks should check out an interview CFO Marcus Kuhnert gave to CNBC.
A fast-changing Merck KGaA is backing away from discovery and preclinical R&D deals it set up with the antibody specialists at Ablynx. And the Belgian biotech saw its shares slide 14% today after news of the prospective breakup--included in Ablynx's annual summary--spread in the markets.
More than three years after Merck KGaA decided to dump its partnership with Milan-based Newron Pharmaceuticals, which in turn iced a planned buyout by Biotie, the Italian biotech has persevered to win European approval to market safinamide as an add-on drug for Parkinson's disease.
After seeing its reputation as a leader in multiple sclerosis erode over recent years, Merck KGaA has decided to carve back the number of staffers working in preclinical R&D in the field.
Merck KGaA, in the process of paring down its pipeline, is walking away from a $625 million deal with Symphogen and handing back the company's lead asset, a targeted cancer treatment in midstage trials.